Further, studies have shown that exosomes transport a variety of cancer
targets, including PD-1 (programmed cell death 1) and its ligands, PD-L1
and PD-L2, probably the most talked about targets in cancer as they are
known to put the brakes on the immune system. Roche has been cast
into the spotlight with news last month that it won the vaunted FDA "Breakthrough Therapy" designation for its PD-L1 drug MPDL3280A.
Roche’s research arm Genentech presented promising data on the
experimental drug at this year’s American Society of Clinical Oncology
conference showing a 43% response rate and evidence of a durable effect
in patients with urothelial bladder cancer.
Click here to receive updates on Aethlon Medical developments:
At what could be considered a blistering pace, relative to typical drug
development, the oncology community seems to be approaching a major
breakthrough that will overcome the shortcomings of chemotherapy and
radiation treatments that are toxic with generally short-lived results.
Immuno-oncology regimens are showing themselves to hold a key to durable
response rates and it seems that combination therapies and new
diagnostic measures are positioning Aethlon and the Hemopurifier in the
thick of this transition to new and better ways to treat cancer.
SOURCE: Emerging Growth LLC